Fig. 1From: A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancerStudy design schema. (Abbreviations: DLT, dose-limiting toxicity; EOT, end of treatment; PK, pharmacokinetic sampling)Back to article page